Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials

Donald E Cutlip1, Manish S Chauhan, Donald S Baim

  • 1Harvard Clinical Research Institute, Boston, Massachusetts 02215, USA. dcutlip@hcri.harvard.edu

Insights

Clinical restenosis after coronary stenting, including target lesion revascularization (TLR), occurs in 12-16% of patients within one year. Angiographic restenosis severity predicts TLR, influenced by factors like diabetes and stent length.

Area of Science:

  • Cardiovascular medicine
  • Interventional cardiology
  • Medical device research

Background:

  • Coronary stenting aims for long-term success, but restenosis and repeat revascularization remain significant challenges.
  • This study analyzes clinical restenosis in a large cohort to understand its predictors and incidence post-stenting.

Purpose of the Study:

  • To evaluate clinical restenosis rates and predictors in a large patient population undergoing coronary stent placement.
  • To compare different definitions of clinical restenosis: target lesion revascularization (TLR), target vessel revascularization (TVR), and target vessel failure (TVF).

Main Methods:

  • Pooled data from 6,186 patients (6,219 lesions) from recent coronary stent trials.
  • Clinical restenosis defined as TLR, TVR, or TVF beyond 30 days post-procedure.
  • Analysis of angiographic follow-up data to correlate with clinical outcomes.

Main Results:

  • One-year rates: 12.2% TLR, 14.3% TVR, 16.0% TVF, significantly higher than six-month rates.
  • Angiographic restenosis severity (> or =50% diameter stenosis) directly correlated with TLR likelihood.
  • Independent predictors of TLR included smaller MLD, longer stent length, diabetes, unstable angina, and hypertension.

Conclusions:

  • Clinical restenosis at one year post-stenting is primarily driven by TLR.
  • Predictors of clinical restenosis align with those for angiographic restenosis.
  • Lower rates of clinical restenosis compared to angiographic were observed due to infrequent TLR in less severe angiographic lesions.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...